SATIVEX SPRAY NOW FOR CANCER PAIN AS WELL

Sativex buccal spray was previously indicated solely for neuropathic pain in multiple sclerosis. In August 2007, it received approval for use in cancer patients who, despite highest dose opioid therapy, still experience moderate to severe pain. On average, cancer pain patients require 8 sprays per day (compared to 5 sprays for MS). Each spray delivers 2.7mg THC (tetrahydrocannabinol) and 2.5mg CBD (cannabidiol) which are thought to act via cannabinoid receptors throughout the CNS. THC is a psychotropic agent which may produce physical and psychological dependence, as well as potential for abuse.

Patients should be screened for heart disease, hypertension, and psychotic disorder.

Patient must be 18 and over.

Application site reactions include stinging and ulceration (rotate site is recommended).

CNS reactions include dizziness, drowsiness, disorientation, memory impairment, confusion.

Psychiatric symptoms include anxiety, illusion, delusion, disorientation, hallucination, paranoia.

Cardiovascular effects include higher pulse rate, hypotension, and fainting episodes.

THC may raise seizure threshold.